Patents by Inventor Amelie Eriksson Karlstrom

Amelie Eriksson Karlstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PNA PROBES FOR PRETARGETED IMAGING AND THERAPY
    Publication number: 20240148917
    Abstract: The invention relates to a kit for targeting of a diagnostic or therapeutic agent to a target site comprising: (a) a first conjugate comprising (i) a targeting moiety capable of binding selectively to the target site; and (ii) a first hybridization probe moiety comprising a PNA oligomer; and (b) a second conjugate comprising (i) a second hybridization probe moiety comprising a complementary PNA oligomer; and (ii) a diagnostic agent or a therapeutic agent moiety; wherein the length of the complementary PNA oligomer in the second hybridization probe moiety is not more than 14 bases. The invention further relates to methods for delivering a diagnostic or therapeutic agent to a target site in mammals, as well as methods for the diagnosis or treatment of medical conditions, such as e.g. cancer, in mammals.
    Type: Application
    Filed: October 18, 2021
    Publication date: May 9, 2024
    Inventors: Amelie Eriksson Karlström, Kristina Westerlund, Hanna Tano
  • ANTI-CD38 SINGLE-DOMAIN ANTIBODIES IN DISEASE MONITORING AND TREATMENT
    Publication number: 20230190968
    Abstract: The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).
    Type: Application
    Filed: May 17, 2021
    Publication date: June 22, 2023
    Applicants: UNIVERSITÉ DE LIÈGE, CENTRE HOSPITALIER UNIVERSITAIRE DE LIÈGE, VRIJE UNIVERSITEIT BRUSSEL, KTH HOLDING AB
    Inventors: Jo CAERS, Elodie DURAY, Mireille DUMOULIN, Matthias D'HUYVETTER, Amelie ERIKSSON KARLSTRÖM
  • Engineered albumin binding polypeptide
    Patent number: 10167322
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present invention relates to albumin binding polypeptides which have a high resistance to proteolytic cleavage and therapeutic use thereof. The disclosure provides an albumin binding polypeptide comprising an albumin binding motif, which motif consists of the amino acid sequence (SEQ?ID?NO.?1782) GXASDX5YKX8X9I?X11X12AX14TVEGVX20?ALX23X24X25ILX28X29XB.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 1, 2019
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Fredrik Frejd, Joel Lindgren, Amelie Eriksson Karlström
  • ENGINEERED ALBUMIN BINDING POLYPEPTIDE
    Publication number: 20160311863
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present invention relates to albumin binding polypeptides which have a high resistance to proteolytic cleavage and therapeutic use thereof. The disclosure provides an albumin binding polypeptide comprising an albumin binding motif, which motif consists of the amino acid sequence (SEQ?ID?NO.?1782) GXASDX5YKX8X9I?X11X12AX14TVEGVX20?ALX23X24X25ILX28X29XB.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 27, 2016
    Inventors: Caroline Ekblad, Fredrik Frejd, Joel Lindgren, Amelie Eriksson Karlström
  • Method for labeling of compounds
    Patent number: 8916689
    Abstract: The present invention relates to site-specific labeling of antibodies or fragments thereof with one or more reporter group(s) in a way that does not affect antigen binding. The method for labeling antibodies and/or fragments thereof, comprises the following steps a) providing an IgG binding protein, which comprises ?-helix structures, with a photoactivatable group and at least one label; b) forming a mixture of said IgG binding protein and the antibodies and/or fragments to be labeled; and c) UV illuminating said mixture for site-specific labeling of said antibodies and/or fragments thereof. The IgG binding protein is preferably the Z domain of Protein A.
    Type: Grant
    Filed: September 5, 2011
    Date of Patent: December 23, 2014
    Assignee: GE Health Bio-Sciences AB
    Inventors: Sophia Hober, Amelie Eriksson Karlstrom, Anna Konrad
  • METHOD FOR LABELING OF COMPOUNDS
    Publication number: 20130184442
    Abstract: The present invention relates to site-specific labeling of antibodies or fragments thereof with one or more reporter group(s) in a way that does not affect antigen binding. The method for labeling antibodies and/or fragments thereof, comprises the following steps a) providing an IgG binding protein, which comprises ?-helix structures, with a photoactivatable group and at least one label; b) forming a mixture of said IgG binding protein and the antibodies and/or fragments to be labeled; and c) UV illuminating said mixture for site-specific labeling of said antibodies and/or fragments thereof. The IgG binding protein is preferably the Z domain of Protein A.
    Type: Application
    Filed: September 5, 2011
    Publication date: July 18, 2013
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Sophia Hober, Amelie Eriksson Karlstrom, Anna Konrad